Vik Hendrickx
Translator — Dutch
Ranst, Belgium
Articles translated into Dutch by Vik Hendrickx
- Roche Phase II GENERATION HD2 study underway
- Update on the PTC Therapeutics PIVOT-HD Trial
- Hereditary Disease Foundation (HDF) conference 2022 – Day 2
- Hereditary Disease Foundation (HDF) conference 2022 – Day 1
- Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials
- Artificial intelligence to save the day? How clever computers are helping us understand Huntington’s disease.
- Revisiting vitamin therapy for HD
- Huntington’s disease therapeutics conference 2022 - Day 3
- Shining a spotlight on huntingtin: a tool to measure huntingtin-lowering in real time
- Huntington’s disease therapeutics conference 2022 - Day 1
- Oral drug may change the story for huntingtin lowering
- Real talk: Q&A with Roche about GENERATION-HD1
- Unpacking recent gene therapy press
- Huntington's disease therapeutics conference 2021 - Day 2
- Huntington’s disease therapeutics conference 2021 - Day 1
- Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus - Day 1
- Treatment for neurological disorder could be repurposed for Huntington’s disease patients
- Working as a team: Changes in brain development mean some brain regions may be slacking off
- HD and Histamines: Targeting Hybrid Receptors to Quiet Stressful Brain Talk
- Fountain of youth: HTT protein repairs neurons by maintaining youthful state
- Huntington’s disease therapeutics conference 2020 - Day 2
- Huntington’s disease therapeutics conference 2020 - Day 1
- Unpacking Wave's PRECISION-HD2 huntingtin-lowering trial announcement
- Details emerge of first Huntington’s disease gene therapy clinical trial
- When interrupting is good: genetic hiccups that protect against Huntington's disease
- Disappointing news from LEGATO-HD trial of laquinimod in Huntington's disease
- Roche announces details of its 'pivotal' huntingtin-lowering study
- HDBuzz Enrolls in Enroll-HD
- A new way of thinking about trials to prevent Huntington's disease
- Ask the expert: Q&A on the huntingtin-lowering trial program
- Precision huntingtin-lowering drug trials target the mutant protein
- Has a "wonder drug" for dementia been discovered? (Spoiler alert: no.)
- FDA approves a new drug for symptoms of Huntington's disease
- A powerful message: does a toxic RNA message molecule cause harm in Huntington's disease?
- The benefits of migration, highlighted in Huntington's disease
- Treasure your exceptions - using outliers to understand Huntington's disease onset and progression
- Early exposure to the HD protein may cause life-long symptoms
- Pfizer Amaryllis trial ends in disappointment: no improvement in Huntington's disease symptoms
- Ultra-rare mutations highlight the importance of the HD gene in brain development
- Sorry folks, the PRIDE-HD trial did NOT show that Pridopidine slows the progression of Huntington's disease
- Slightly long CAG repeats are more common than we thought
- Huntington's Disease Therapeutics Conference 2016 - day 2
- Huntington's Disease Therapeutics Conference 2016 - day 3
- Huntington's Disease Therapeutics Conference 2016 - day 1
- Harnessing the power of viruses to treat Huntington's disease
- New tool to measure outcomes in Huntington’s Disease clinical trials
- Mapping the anatomy of HD: a whole-brain history
- A faulty filter? Blood vessel changes in Huntington's disease
- Lighting the way: A new biomarker for Huntington’s disease
- Positive results announced for re-worked tetrabenazine drug in Huntington's disease
- HD mice provide a useful failure
- Melatonin alterations in Huntington's disease help explain trouble with sleep
- 2CARE study of coenzyme Q for Huntington's disease ends in disappointment
- Illuminating the progression of Huntington’s disease
- Huntington's disease clinical trial announcement: huntingtin-lowering drug to enter Phase I trial in 2015
- EuroBuzz 2014 Video, day one
- Raptor announces results of cysteamine trial for Huntington's disease
- Huntington's Disease Therapeutics Conference 2014: day 3
- Prana announces results of Reach2HD trial of PBT2 for Huntington's disease
- Is a new Huntington’s Disease drug study on the right Trk?
- Buzzilia Video: Day 2
- The sweet lowdown: Huntington's disease brains use sugar differently
- What the 'big neurodegeneration breakthrough' means for Huntington's disease
- Video feature: Huntington's disease research... in space!
- HD Therapeutics Conference 2013 Updates: Day 3
- Simple rules for a good night's sleep in Huntington's disease
- HD Therapeutics Conference 2013 Updates: Day 1
- The 'N17' region of huntingtin protein: an address label in Huntington's disease?
- Coming Soon: EuroBuzz 2012
- ASO gene silencing reaches further, lasts longer
- Does the HD mutation affect children's growth?
- Interview: CHDI's scientific team
- Closing the care gap: new guidelines for HD care
- Mutant yeast highlights crucial CAG-reading protein
- New analysis suggests 'small' CAG length doesn't matter after all
- Melatonin treatment success in HD mice
- HDAC inhibitor drug protects memory in HD mice
- HD just got cilia
- HD World Congress 2011: a retrospective
- HDAC inhibitors and a possible 'blood biomarker'
- Re-routing the huntingtin protein inside cells
- Making babies: having a family, the HD way